Skip to main content
Livermore
Livermore
ZHEN

Great Point Partners LLC

SEC CIK
0001281446
Latest filing
Aug 14, 2026

Holdings in Q3 2021

Holdings as of Sep 30, 2021, filed Nov 15, 2021. Long positions only; changes compare share counts with Q2 2021.

Institution overview
Positions
35
+7 vs. Q2 2021
Portfolio value
$422.9M
−$24.3M (−5.4%) vs. Q2 2021
Filed
Nov 15, 2021
SEC
Holdings of Great Point Partners LLC in Q3 2021
SecurityClassSharesValue% of portfolioShare changeActionHistory
PRQRProQR Therapeutics N.V.SHS EURO30,336$254.0K0.1%+30,336NewHistory
IFRXInflaRx N.V.COM551,918$1.43M0.3%−1,648,082−74.9%ReducedHistory
FOLDAmicus Therapeutics, Inc.COM249,000$2.38M0.6%−1,351,000−84.4%ReducedHistory
COLLCollegium Pharmaceutical, IncCOM121,342$2.40M0.6%−740,068−85.9%ReducedHistory
RPTXRepare Therapeutics Inc.COM93,137$2.44M0.6%−342,952−78.6%ReducedHistory
PCVXVaxcyte, Inc.COM98,061$2.49M0.6%+98,061NewHistory
KNSAKiniksa Pharmaceuticals International, plcCOM CL A480,000$5.47M1.3%+480,000NewHistory
PHATPhathom Pharmaceuticals, Inc.COM220,863$7.09M1.7%+220,863NewHistory
SYRESpyre Therapeutics, Inc.COM900,000$7.16M1.7%00.0%UnchangedHistory
RIGLRigel Pharmaceuticals IncCOM NEW1,980,000$7.19M1.7%+480,000+32.0%AddedHistory
CTMXCytomX Therapeutics, Inc.COM1,500,000$7.63M1.8%+500,000+50.0%AddedHistory
DNTHDianthus Therapeutics, Inc.COM1,170,000$8.52M2.0%+58,889+5.3%AddedHistory
RFLRafael Holdings, Inc.COM CL B285,714$8.78M2.1%+285,714NewHistory
ACRSAclaris Therapeutics, Inc.COM500,000$9.00M2.1%+500,000NewHistory
NKTRNektar TherapeuticsCOM504,691$9.06M2.1%+504,691NewHistory
OLMAOlema Pharmaceuticals, Inc.COM329,086$9.07M2.1%00.0%UnchangedHistory
PBYIPuma Biotechnology, Inc.COM1,300,000$9.11M2.2%00.0%UnchangedHistory
TCDATricida, Inc.COM1,974,000$9.16M2.2%00.0%UnchangedHistory
XENEXenon Pharmaceuticals Inc.COM700,000$10.7M2.5%+700,000NewHistory
SAGESage Therapeutics, Inc.COM269,010$11.9M2.8%+19,010+7.6%AddedHistory
DYNDyne Therapeutics, Inc.COM745,000$12.1M2.9%+72,441+10.8%AddedHistory
URGNUroGen Pharma Ltd.COM750,000$12.6M3.0%+750,000NewHistory
BIIBBiogen Inc.COM47,500$13.4M3.2%+15,000+46.2%AddedHistory
CYTKCytokinetics IncCOM NEW391,429$14.0M3.3%+391,429NewHistory
ANABAnaptysbio, IncCOM549,545$14.9M3.5%+149,494+37.4%AddedHistory
TVTXTravere Therapeutics, Inc.COM625,000$15.2M3.6%−459,300−42.4%ReducedHistory
VRTXVertex Pharmaceuticals IncStock85,000$15.4M3.6%+85,000NewHistory
UTHRUnited Therapeutics CorpCOM86,667$16.0M3.8%−89,739−50.9%ReducedHistory
DRNADicerna Pharmaceuticals IncCOM799,999$16.1M3.8%+799,999NewHistory
MGNXMacrogenics IncCOM1,000,000$20.9M5.0%−378,495−27.5%ReducedHistory
RCKTRocket Pharmaceuticals, Inc.COM765,000$22.9M5.4%−52,040−6.4%ReducedHistory
BCABBioAtla, Inc.COM844,002$24.8M5.9%+844,002NewHistory
KDMNKadmon Holdings, Inc.COM3,375,000$29.4M7.0%−1,455,000−30.1%ReducedHistory
ARNAArena Pharmaceuticals IncCOM NEW530,670$31.6M7.5%+25,000+4.9%AddedHistory
EXELExelixis, Inc.COM1,525,000$32.2M7.6%+130,893+9.4%AddedHistory

Options (1)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Great Point Partners LLC in Q3 2021
SecurityClassPutsCalls
APLSApellis Pharmaceuticals, Inc.COM–$6.59M

Sold out since Q2 2021 (6)

Positions held at the end of Q2 2021 that are gone from this filing.

Positions of Great Point Partners LLC sold out since Q2 2021
SecurityClassShares in Q2 2021Value in Q2 2021% of portfolio in Q2 2021History
PODDInsulet CorpStock104,600$28.7M6.4%History
MRTXMirati Therapeutics, Inc.COM100,000$16.2M3.6%History
OCULOcular Therapeutix, IncCOM919,887$13.0M2.9%History
XENTIntersect ENT, Inc.COM700,000$12.0M2.7%History
KURAKura Oncology, Inc.COM500,000$10.4M2.3%History
VERVVerve Therapeutics, Inc.COM35,000$2.11M0.5%History